Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
Leah Gajecki
, Irina V. Lebedeva
, Yu Rou Liao
, Daisy Ambriz
, Lukas M. Carter
, Melina Kumpf
, Samantha Lovibond
, Justin S. Hachey
, Maya S. Graham
, Michael Postow
, Jason S. Lewis
, David P. Andrew
, Manuel Baca
, Heiko Schöder
, Steven M. Larson
, Darren R. Veach
,
Simone Krebs
Nuclear Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Solid Malignancies
100%
Targeting Antibodies
100%
Immuno
100%
Interleukin-13 Receptor α2
100%
Tumoral
50%
Melanoma Model
50%
U87MG
50%
Lutetium-177 (177Lu)
50%
Prospective Dosimetry
50%
Monoclonal Antibody
33%
Glioblastoma
33%
Healthy Tissue
33%
In Vivo Biodistribution
33%
Target Specificity
33%
Tracer Injection
33%
Anti-interleukin
33%
Pico
16%
Mouse Model
16%
Melanoma
16%
Injected Activity
16%
Binding Affinity
16%
In Vitro Study
16%
Binding Targets
16%
Xenograft
16%
Human Melanoma
16%
Blood Pool
16%
A375
16%
Therapeutic Index
16%
High Contrast
16%
Cell Surface Receptor
16%
Radioimmunotherapy
16%
Injected Dose
16%
In Vitro Binding
16%
Therapeutic Efficacy
16%
Binding Properties
16%
Human Glioblastoma
16%
Xenograft Model
16%
PET Image
16%
PET Study
16%
Tumor Delineation
16%
Dose Optimization
16%
Dose Titration
16%
Targeted Radioimmunotherapy
16%
Titration Experiment
16%
Zirconium-89 (89Zr)
16%
89Zr-immuno-PET
16%
Mass Dose
16%
Target Binding
16%
Glioblastoma Model
16%
High Contrast Image
16%
Pharmacology, Toxicology and Pharmaceutical Science
Polyethylene Terephthalate
100%
Immunoglobulin
100%
Interleukin 13 Receptor
100%
Melanoma
66%
Glioblastoma
50%
Dosimetry
50%
Tracer
50%
Lutetium 177
50%
Biodistribution
33%
Zirconium 89
33%
Neoplasm
16%
Monoclonal Antibody
16%
Mouse Model
16%
Therapeutic Window
16%
Human Monoclonal Antibody
16%
Cell Surface Receptor
16%
Immunology and Microbiology
Intravenous Immunoglobulin
100%
Interleukin-13 Receptor
100%
In Vitro
50%
Xenograft
33%
Monoclonal Antibody
16%
Mouse Model
16%
Binding Affinity
16%
Cell Surface
16%
Human Monoclonal Antibody
16%
Isotope Labeling
16%
Drug Dose Titration
16%